Evidence map›Paper›PMID 32149469›Full record

ArticleJournal of diabetes investigation2020

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.

Ikuro Matsuba, Takehiro Kawata, Kotaro Iemitsu, Taro Asakura, Hikaru Amemiya, Masashi Ishikawa, Syogo Ito, Mizuki Kaneshiro, Akira Kanamori, Akira Kubota and 14 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Ikuro MatsubaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.ORCID https://orcid.org/0000-0002-4363-5036
Takehiro KawataThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Kotaro IemitsuThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Taro AsakuraThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Hikaru AmemiyaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Masashi IshikawaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Syogo ItoThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Mizuki KaneshiroThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Akira KanamoriThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Akira KubotaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Kazuaki ShinodaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Masahiko TakaiThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Tetsuo TakumaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Masahiro TakihataThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Hiroshi TakedaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Keiji TanakaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Yoko MatsuzawaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Hideo MachimuraThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Fuyuki MinagawaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Nobuaki MinamiThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Atsuko MokuboThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Masaaki MiyakawaThe Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Yasuo TerauchiDepartment of Endocrinology and Metabolism, Yokohama City University, Yokohama, Japan.ORCID https://orcid.org/0000-0002-8872-3697
Yasushi TanakaDivision of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Kanagawa Prefecture Medical Association · JPSt. Marianna University School of Medicine · JPYokohama City University · JP

Funding

Astellas Pharma Inc N/A
6 · The paper itself

Abstract

AIMS/

introductionType 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available.

methodsThis was an investigator-initiated multicenter prospective intervention study in which ipragliflozin (50 mg) was administered once daily, and glycemic control, estimated glomerular filtration rate (eGFR) and adverse events were evaluated until 104 weeks after starting research.

resultsThere were 407 patients analyzed. In the eGFR ≥90 group and eGFR ≥60 to <90 group, eGFR had significantly decreased compared with baseline at all time points from 4 to 104 weeks. There were significant increases in the eGFR ≥45 to <60 groups compared with baseline at 36 weeks (2.3 ± 1.0) and 52 weeks (2.6 ± 1.2). Comparison between the eGFR <60, urine albumin-to-creatinine ratio >300 group and the eGFR <60, urine albumin-to-creatinine ratio <300 group showed a greater reduction in eGFR in the former (-5.4 ± 2.4 vs 3.3 ± 1.1) at 12 weeks and was maintained to 104 weeks. In any group, eGFR did not significantly decrease until 104 weeks compared with 4 weeks. The urine albumin-to-creatinine ratio after 52 weeks and after 104 weeks was significantly decreased compared with baseline in the eGFR ≥90 group.

conclusionsIpragliflozin lowers eGFR and corrects hyperfiltration in patients with high eGFR (eGFR ≥60). In patients with low eGFR (eGFR ≥30 to <60), ipragliflozin has the possibility of increasing eGFR and exerting a renoprotective effect.

Indexed as

AgedBiomarkersBlood GlucoseDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleFollow-Up StudiesGlomerular Filtration RateGlucosidesGlycated HemoglobinHumansMaleMiddle AgedPrognosisProspective StudiesRenal Insufficiency, ChronicBiomarkersBlood GlucoseGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanipragliflozinSodium-Glucose Transporter 2 InhibitorsThiophenesDiabetic nephropathyIpragliflozinSodium-glucose cotransporter 2 inhibitor

Identifiers

PMID32149469
PMCPMC7477528
OpenAlexW3012170683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.